The COST Action “European Network to Advance Best practices & technoLogy on medication adherencE” (ENABLE) CA19132 aims to create a multidisciplinary network of relevant stakeholders that work collaboratively towards economically viable implementation of medication adherence enhancing technologies across different European healthcare systems.
For full information see the Action’s Memorandum of Understanding (MoU) – chapter 1.
Due to an ageing society, there is a steady increase in chronic diseases and multi-morbidity in Europe. This requires a multidisciplinary response, which often involves lifestyle changes combined with lifetime medication use.
Technological advances (e.g. smart pillboxes, digital inhalers, tracking devices, e-injection pens, e-Health, big data), have significant potential to support healthcare professionals and empower patients in detecting and managing non-adherence.
What is already known about medication adherence
What is this project focused on delivering to it's public
What is this projects approach to the challenges up ahead
The specific objectives of this Action are:
● Benchmark, assess and raise awareness on current practices on tackling non-adherence in different healthcare settings across Europe. This entails the exchange of best practices, facilitators/barriers, experiences and expertise of different healthcare providers (GPs, specialists, pharmacists, nurses, health psychologists) and patients in dealing with non-adherence issues in daily life and practice.
● Accelerate the availability and implementation of adherence enhancing technologies across Europe. This entails the exchange (e.g. through webplatforms, social media) of multidisciplinary knowledge and creates awareness among healthcare providers on the availability and potential of innovative adherence measurement methods and adherence enhancing technology for clinical practice.
● Gather expert input for future market applications and implementation of cutting-edge adherence
enhancing technology. Knowledge exchange on cost-effectiveness, patient access pathways, and reimbursement could help the implementation.
● Bringing together currently isolated stakeholders and building up a network to achieve breakthroughs in the development of new process to advance the implementation of adherence enhancing technologies. This will be achieved by hosting meetings, workshops and conferences.
● Developing a platform to exchange and foster adherence knowledge, including a repository of best practices and technologies that can enhance medication adherence. Per intervention, an independent assessment of its effectiveness and cost-effectiveness will be provided by a panel of multidisciplinary experts.
● Translate and disseminate knowledge on technologies to specific target groups such as Early Career Investigators (ECIs) and researchers from less research-intensive countries. This will be achieved by hosting meetings and workshops, organizing Training Schools and opportunities for Short-Term Scientific Missions (STSMs).
In the short term impact several important scientific and technological impacts are anticipated due to increased multidisciplinary and private-public collaboration on medication adherence.
For full information see the Action’s Memorandum of Understanding (MoU) – chapter 3.
ENABLE will tackle a highly relevant issue with substantial cross-sectorial impact. Systematic reviews indicate a wide-ranging negative impact of non-adherence, and reveal consistent associations of nonadherence to worse clinical (i.e. 200,000 deaths) as well as economic outcomes (i.e. €80-125 billion) across the full spectrum of chronic diseases.
For full information see the Action’s Memorandum of Understanding (MoU) – chapter 3.
Information generated and disseminated through the ENABLE Action will stimulate SMEs and investors even more to develop medical technology (technological impact), being guided by easily accessible local medication adherence expertise centers and a pan-European web platform that help them to reach their end-users and give them a better and more transparent idea of their potential European market share.
For full information see the Action’s Memorandum of Understanding (MoU) – chapter 2.
As compared to existing efforts outlined above, the ENABLE COST Action will have a unique and specific focus that goes beyond the objectives of the existing efforts. It will be disease and discipline overarching, is multidisciplinary (providers, patients, policy makers), incorporates the latest state-of- the-art adherence enhancing technology through SME involvement and has a strong focus on sustainable, cost-effective implementation across Europe.
For full information see the Action’s Memorandum of Understanding (MoU) – chapter 2.
